SENS

Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow persist.

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.